Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | MMED | EPAM |
|---|---|---|
| Price | $20.16 | $109.95 |
| Change today | ▲ 2.34% | ▲ 1.53% |
| Market cap | $5.67B | $5.67B |
| Return, 3 months | +31.2% | +22.8% |
| Return, year to date | – | -46.3% |
| Return, 1 year | – | -27.9% |
| P/E (TTM) | -17.9 | 14.9 |
| P/B | 1.6 | 1.6 |
| P/E percentile vs own 5y | – | – |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | – | – |
| Analyst buy share | – | – |
| RSI (14) | 46 | 49 |
| 30-day volatility | 48.1% | 39.9% |
| Max drawdown, 1 year | -41.6% | -65.7% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | – | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
